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Background. Infections with Strongyloides stercoralis are of considerable public health relevance. Moxidectin, a well-established 
drug in veterinary medicine under consideration for regulatory submission for the treatment of onchocerciasis, might serve as an 
alternative to the widely used ivermectin.
Methods. We conducted an exploratory, randomized, single-blind trial to evaluate the efficacy and safety of moxidectin (8 mg) 
vs ivermectin (200 μg/kg) against S. stercoralis infections. Cure rate (CR) against S. stercoralis was the primary outcome. Safety and 
efficacy against coinfections with soil-transmitted helminths and Opisthorchis viverrini were secondary outcomes. Noninferiority 
required the lower limit of the 95% confidence interval (CI) of the differences in CRs not exceed 7 percentage points.
Results. A total of 127 participants were enrolled and randomly assigned to the 2 treatments whereby 1 participant per arm was 
lost to follow-up. We observed a CR of 93.7% (59/63) for moxidectin compared to 95.2% (59/62) for ivermectin. Differences between 
CRs were estimated as –1.5% percentage points (95% CI, –9.6 to 6.5), thus the lower limit of the CI exceeds the noninferiority margin 
of 7 percentage points. No side effects were observed. CRs against hookworm infection were 57% (moxidectin) and 56% (ivermec-
tin). Low efficacy for both drugs against O. viverrini was observed.
Conclusions. Moxidectin might be a safe and efficacious alternative to ivermectin for the treatment of S. stercoralis infection, 
given that only slight differences in CRs were observed. However, noninferiority could not be demonstrated. Larger clinical trials 
should be conducted once the drug is marketed.
Clinical Trials Registration. Current Controlled Trials:  ISRCTN11983645
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Strongyloides stercoralis is a soil-transmitted nematode and 
one of the most overlooked helminths among the neglected 
tropical diseases. It exists throughout the world, excluding 
only the far North and South, yet estimates of its prevalence 
(about 100 million people) are often only little more than 
educated guesses and probably largely underestimated [1–3]. 
Compared to other major soil-transmitted helminths (STHs), 
information on S. stercoralis is scarce [4]. Strongyloides ster-
coralis is an exception among helminthic parasites as it can 
reproduce within a human host (endogenous autoinfection), 
which may result in long-lasting infections. Some studies 
have reported on individuals who had S. stercoralis infections 
sustained for more than 75  years. Strongyloides stercoralis’ 
ability to cause systemic infection is another exceptional 
feature of this threadworm [3]. However, most infections, 
chronic, low-intensity infections in particular, remain asymp-
tomatic. It has been found that S. stercoralis infection occurs 
often in adults [4, 5].
The current recommended treatments are a single dose of 
ivermectin or albendazole for 3 consecutive days, which has 
a lower efficacy [1, 5, 6]. Ivermectin is highly effective against 
S. stercoralis infection, characterized by a high cure rate (CR). 
Several trials conducted in Southeast Asia on S.  stercoralis 
reported a CR for ivermectin of 97%–99% [6–10]. Despite this, 
new drugs are needed. Among new candidates in the human 
anthelminthic drug development pipeline is moxidectin, a mac-
rocyclic lactone that is well established in veterinary practice 
[11]. In vivo studies on Strongyloides fuelleborni conducted on 
rhesus macaques infections reported the efficacy of moxidectin 
to be similar to that of ivermectin [12]. Moxidectin is currently 
under consideration by the US Food and Drug Administration 
(FDA) for use against onchocerciasis in humans. The drug 
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might offer some advantages over ivermectin. First, moxidectin 
use is weight independent at an 8-mg fixed dose, simplifying 
administration, especially when treating large communities. 
Second, moxidectin has been shown to have a lower neurotoxic 
potential than ivermectin [13]. Finally, and most importantly, 
moxidectin has been used successfully in veterinary medicine 
against ivermectin-resistant strains of Haemonchus contortus 
[14].
Our aim in this study was to assess, for the first time, the effi-
cacy of moxidectin against S. stercoralis infections. Ivermectin 
served as the comparator. The safety of moxidectin and its effi-
cacy against coinfections with Opisthorchis viverrini and STHs 
were evaluated as secondary outcomes.
METHODS
Ethical Considerations
Ethical clearance was obtained from the ethics committee 
of Northwestern and Central Switzerland and from the Lao 
National Ethics Committee on Health Research Ministry of 
Health. The trial is registered with Current Controlled Trials 
(ISRCTN11983645). Participants aged 12–60 years were eligible 
for inclusion. Written informed consent was collected from all 
participants or legal guardians for children before enrollment.
Randomization and Drugs
We used a computer-generated block randomization code 
(block size of 4)  provided by an independent statistician. 
Enrolled participants were randomly allocated to the follow-
ing 2 treatment arms: ivermectin 200-µg/kg single dose or 
moxidectin 8-mg single dose. Moxidectin was administered 
as an oral suspension (Cydectin 0.1%; Zoetis, Switzerland) 
mixed with equal amounts of mint syrup (sweetener Premix 
CY/SA S741 from Sanaro SA, Switzerland) containing E952 
(sodium cyclamate), E954 (sodium saccharin), and pepper-
mint aroma (Permaseal from Givaudan AG, Switzerland) to 
mask the drug’s bitter taste. Ivermectin (Iver P; 3-mg tablets), 
obtained from Elea, Argentina, was administered based on 
patient weight (200  µg/kg). Only the principal investigator 
was aware of the treatment assignments, while laboratory 
technicians were blinded. Patients were not informed whether 
they would receive ivermectin or moxidectin, though we 
cannot exclude the possibility that the patients recognized 
ivermectin tablets if they had been treated with it in earlier 
treatment campaigns.
Study Procedures and Diagnosis
This exploratory, phase 2, randomized, single-blind study 
was conducted between April and June 2016 in the district of 
Pathoumphone, Lao People’s Democratic Republic, which is 
endemic for S. stercoralis infection. CR against S. stercoralis, 
determined 21 days after treatment, was the primary outcome. 
Safety, CR, and egg reduction rate (ERR) against coinfections 
with STHs and O. viverrini were the secondary outcomes. In 
both locations, village-based recruitment was implemented.
 At baseline 2 fecal samples on 2 consecutive days were 
collected from participants. Samples were examined with the 
Baermann method for the detection of S. stercoralis larvae. The 
Baermann method was performed following the World Health 
Organization standard procedure [15]. Only participants posi-
tive for the infection were included in the study. Concomitant 
infections with STHs (Ascaris lumbricoides, Trichuris trichiura, 
and hookworm) and O. viverrini were assessed using the Kato-
Katz method [16]. Height was measured with a standard meter 
(to the nearest 1  cm) and weight with an electronic balance 
(to the nearest 0.1 kg). The medical history of participants was 
assessed with a standardized questionnaire in addition to a clin-
ical examination carried out by the study clinician. Participants 
who had chronic diseases, were aged <12 years, were pregnant 
women, or were considered not healthy at physical examination 
were excluded from the trial but still given the recommended 
treatment. Side effects were monitored at 3, 24, and 48 hours 
after treatment.
Between day 21 and day 25 after treatment, we resampled 2 
stool specimens for analysis of S. stercoralis, STHs, and O. viver-
rini. At the end of the study, all participants who were still pos-
itive for S. stercoralis, STHs, and/or O. viverrini infections were 
treated with ivermectin (200 μg/kg), albendazole (400 mg) and/
or praziquantel (40 mg/kg) according to local guidelines.
Sample Size and Statistical Analyses
This study was designed as a binary outcome noninferiority 
trial. The sample size determination was based on the assump-
tions that the efficacy of moxidectin against S. stercoralis has 
not yet been studied and that it is well known that the efficacy 
of ivermectin is high (97%–99%) [7–10, 17]. Since the mode 
of action of both drugs is similar, we assumed a CR of 98% for 
both drugs. The noninferiority limit was set to 7 percentage 
points. With no difference between both drugs, 100 patients 
(50 per arm) would yield an upper limit of the 95% confidence 
interval (CI) that excludes a difference of more than 7% with a 
power of 80%. The sample size was increased to 60 per arm to 
account for a potential loss to follow-up of 15%.
We based the screening on reported prevalence data of 40% 
on Mekong islands [18]. Hence, we anticipated screening 350 
participants for the detection of at least 120 infected with S. ster-
coralis, including a safety margin. However, this number had to 
be increased since the proportion of participants who provided 
2 stool samples was lower than expected.
Data were digitally collected on tablets using CommCare 
ODK, version 2.8. The questionnaires and forms were devel-
oped in the CommCare server (www.commcarehq.org) and 
tested previous to the field activity. A mobile user was created 
for each field data collector allowing access to a specific form. 
A completed form was immediately synchronized to the server 
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for real time data monitoring. After fieldwork, data was down-
loaded from the server into Excel (version 2011). All data was 
crossed-checked for completeness and consistency. A hard copy 
of the forms was also completed during data collection and 
used to cross-check 10% of the electronically collected data. 
Validated data were cross-checked and analyzed with Stata 
12.0 (College Station, Texas). A barcode generating system 
was applied using a free-barcode generator software available 
at www.free-barcode.com. A generated barcode containing the 
UID of each patient was placed on the stool containers before 
handing them to patients. Once a filled stool container arrived 
at the research station, a research team member scanned the 
attached barcode for sample registration and subsequently the 
system automatically generated a specific form for further data 
entry. An available case analysis, which included all partici-
pants with primary outcome data, and a per-protocol analysis 
were planned. CRs were calculated as the percentage of par-
ticipants who became larvae-negative after treatment, being 
larvae positive at baseline. Bootstrap resampling methods with 
2000 replicates were used to calculate 95% CIs for ERRs. CIs 
indicate statistical significance. For the secondary outcome 
parameters, the intensity of infection of O. viverrini and STHs 
in terms of eggs per gram (EPG) was assessed by adding up 
the egg counts from the quadruplicate Kato-Katz thick smears 
(from baseline and follow-up separately) and multiplying this 
number by a factor of 6. Geometric and arithmetic mean egg 
counts were calculated for each group before and after treat-
ment for O. viverrini and STHs infections. Intensity of infec-
tion for O. viverrini was categorized considering 600, 1500, and 
6000 EPG as cutoffs [19]. Intensity of infection for hookworm 
was categorized considering 2000 and 4000 EPG as cutoffs 
[20]. ERRs were calculated using the following formula: ERR 
= [1 – (geometric mean at follow-up/geometric mean at base-
line)] × 100. CRs for STHs and O. viverrini were calculated as 
the percentage of participants who became egg-negative after 
treatment, being egg-positive at baseline. Analyses were per-
formed with Stata (version 12.1).
RESULTS
Baseline Characteristics and Study Flow
The study flow chart is presented in Figure 1. We screened 571 
participants, of which 153 were negative for infection, 283 did 
not provide any/enough stool sample, and 8 were excluded at 
the physical examination because they did not meet the inclu-
sion criteria. In total, 127 participants were enrolled and ran-
domly assigned to 1 of the 2 treatments as follows: 64 received 
moxidectin (8 mg) and 63 were treated with ivermectin (200 
µg/kg). In each treatment arm 1 patient was not present at the 
follow-up examination (Figure 1). No deviations from the treat-
ment protocol were observed; therefore, the available case anal-
ysis is identical with the per-protocol analysis.
Demographic and clinical baseline characteristics are sum-
marized in Table 1. Treatment groups were well balanced in 
terms of age (mean age, 40 years), sex (51% male participants), 
weight (mean weight, 54 kg), and height (mean height, 158 cm).
Coinfections were more often observed in the moxidectin 
arm, in which the proportions of O. viverrini and hookworm 
infections were 89% and 58%, respectively, compared to 75% 
and 56% of patients, respectively, in the ivermectin arm. Most 
infections with O. viverrini and hookworm were of light infec-
tion intensity. No coinfections with other helminths were 
detected among participants in both treatment arms.
Efficacy Against S. stercoralis
We observed a high efficacy of both drugs against S. stercora-
lis infection. Moxidectin achieved a CR of 93.6% (59/63; 95% 
CI, 84.5 to –98.2) compared to a CR of 95.1% (59/62; 95% CI, 
86.5 to 99.0) calculated for ivermectin (Table  2). Differences 
between CRs were estimated as –1.5 percentage points (95% CI, 
–9.6 to –6.5). Therefore, the lower limit of the 95% CI exceeds 
the preset noninferiority margin of 7 percentage points.
Efficacy Against Coinfections
A moderate efficacy was observed against hookworm infection in 
both treatment arms. The CRs and ERRs for moxidectin and iver-
mectin were 56.7% (21/37; 95% CI, 55.9% to 79.7%) and 55.9% 
(19/34; 95% CI, 52.1% to 84.7%) and 74.6% (95% CI, 61% to 90%) 
and 79.4% (95% CI, 61% to 88%), respectively. None of the drugs 
showed activity against O. viverrini. CRs were 17.8% (10/56; 95% 
CI, 11.2% to 32.2%; moxidectin) and 6.5% (3/46; 95% CI, 6.4% to 
25.4%; ivermectin) with corresponding ERRs of 12.5% (95% CI, 
–2% to 30%) and 0% (95% CI, –40% to 2%; Table 2).
Safety
At clinical examination, 37 (29.1%) participants reported 
symptoms before treatment. Most had vertigo (13.4%) and 
headache (8.6%). In addition, a few participants reported 
Figure  1. Flow chart of the study conducted in the villages of Morphu and 
Phakpheo in Champasack Province, Lao People’s Democratic Republic, between 
April 2016 May 2016.
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nausea, diarrhea, abdominal discomfort, and skin lesions. 
One adult reported blood in stool. Participants were checked 
at 3, 24, and 48 hours after drug administration for side 
effects. None of the participants reported any side effect from 
treatment at any time point.
DISCUSSION
This is the first randomized trial to assess the efficacy of mox-
idectin against S. stercoralis infection, which is a neglected yet 
considerable public health problem. Despite the high efficacy 
and safety of ivermectin, which is the current drug of choice, it 
is crucial to develop and find alternative treatments in case iver-
mectin resistance arises. Other available drugs, that is, the ben-
zimidazoles (albendazole), need longer treatment courses and 
are less efficacious [6]. No new drugs are under development 
for S. stercoralis infection [21]. Repurposing of drugs currently 
used or under registration for different indications might be a 
fast and cost-effective way to discover novel molecules effective 
against this infection [22].
Moxidectin, which is widely used in veterinary medicine 
[11], is a “low hanging fruit” to be repositioned for treatment of 
S. stercoralis infection, given the good results observed in vivo 
against S. fuelleborni infection in macaques [12] and the nearly 
completed FDA registration for treatment of onchocerciasis in 
humans.
Moxidectin showed promising efficacy against S.  stercoralis 
infection in our trial, comparable to that of ivermectin (94% 
vs 95%, respectively). Of note, although CRs for ivermectin of 
between 97% and 99% have been repeatedly reported in similar 
settings [9, 10], the sample size relied on the optimistic assump-
tion of 98% CR. Since the observed CRs were lower, the study 
was underpowered and noninferiority could not be demon-
strated at the prespecified margin.
Both drugs were very well tolerated in our study; none of the 
participants reported side effects after treatment. As reported 
in the literature, ivermectin was well tolerated, with a similar 
number of side effects observed in the ivermectin and placebo 
groups [23–25]. A recent study that used the same formulation 
of moxidectin in children infected with Schistosoma man-
soni and Schistosoma haematobium reported mild side effects 
including nausea, headache, and abdominal discomfort [26]. 
One possible explanation might be related to the age of partic-
ipants (adults vs school-age children) who perceive symptoms 
and physical discomfort in different ways. Moreover, adults 
better understand physical symptoms and are more critical and 
reliable in reporting them. Another possible reason might be 
linked to the fact that in the cited study, all participants reported 
similar symptoms before and after treatment, hence it cannot 
be determined whether symptoms are treatment related or not.
As highlighted above, one key advantage of moxidectin over 
ivermectin is that it might be effective against ivermectin- 
resistant S. stercoralis. Fortunately, anthelminthic resistance 
has not yet been observed in humans. Nevertheless, it is worth 
highlighting that resistance has been demonstrated in sheep 
infected with Strongyloides spp. (40%) following treatment 
with ivermectin, even at low frequency [27]. Different studies 
in veterinary medicine have demonstrated that moxidectin is 
effective against ivermectin-resistant strains of parasites [14]. 
One trial conducted on lambs showed an efficacy of >99% 
against resistant Haemonchus contortus, whereas the CRs of 
Table 2. Efficacy of Moxidectin and Ivermectin Against Strongyloides 
stercoralis and Coinfections
Study Parameter Moxidectin (N = 63) Ivermectin (N = 62)
Strongyloides stercoralis
Participants cured, N 
(%) (CI)
59/63 59/62
(93.6) (84.5 to 98.2) (95.1) (86.5 to 99.0)
Opisthorchis viverrini
EPG before treatment 
AM (CI)
276.7 (51.3 to 502.1) 248.1 (65.5 to 430.8)
EPG after treatment 
AM (CI)
169.1 (51 to 287.2) 191.2 (58.6 to 323.7)
EPG before treatment 
GM (CI)
44.6 (27.1 to 73.2) 32.1 (17.1 to 59.3)
EPG after treatment 
GM (CI)
27.6 (15.7 to 47.9) 49.7 (23.8 to 65.8)
Egg reduction rate 
(%) (CI)
12.5 (–2 to 30) 0 (–40 to 2)
Participants cured, N 
(%) (CI)
10/56 
(17.8) (11.2 to 32.2)
3/46
(6.5) (6.4 to 25.4)
Hookworm
EPG before treatment 
AM (CI)
149.1 (47.9 to 250.3) 432.9 (0 to 1192.2)
EPG after treatment 
AM (CI)
34.8 (11.9 to 57.7) 23.7 (8.1 to 39.3)
EPG before treatment 
GM (CI)
11.4 (5.7 to 22.1) 7.3 (3.6 to 13.9)
EPG after treatment 
GM (CI)
2.9 (1.0 to 4.4) 1.5 (0.6 to 3.0)
Egg reduction rate 
(%) (CI)
74.6 (61 to 90) 79.4 (61 to 88)
Participants cured, N 
(%) (CI)
21/37 
(56.7) (55.9 to 79.7)
19/34 
(55.9) (52.1 to 84.7)
Abbreviations: AM, arithmetic mean; CI, 95% confidence interval; EPG, eggs per gram; 
GM, geometric mean.
Table 1. Baseline Characteristics of Strongyloides stercoralis–Infected 
Participants Stratified by Treatment Group
Characteristic Moxidectin (N = 64) Ivermectin (N = 63)
Age [y], mean (SD) 39.4 (12.9) 40.7 (10.9)
Males, N (%) 31 (48.4) 34 (54.0)
Weight [kg], mean (SD) 54.4 (10.2) 52.5 (9.3)
Height [cm], mean (SD) 157.5 (7.5) 158.2 (7.5)
Temperature [°C], mean (SD) 36.4 (0.5) 36.4 (0.4)
Coinfection with Opisthorchis 
viverrini, N (%)
57 (89.1) 47 (74.6)
Coinfection with hookworm,  
N (%)
37 (57.8) 35 (55.6)
Abbreviation: SD, standard deviation.
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ivermectin were only 38%–53% [28]. Resistance against iver-
mectin was found to be a dominant trait, while it might be ren-
dered incompletely dominant or recessive for moxidectin [29]. 
Cross-resistance among macrocyclic lactones has been reported 
in livestock; this impairs efficacy of multiple compounds [14, 
27, 30]. Despite this fact, it has been shown that drugs develop 
resistance at different speed, and resistance toward moxidectin 
occurs more slowly than for ivermectin. Moreover, moxidec-
tin at recommended dosages was shown to be effective against 
ivermectin-resistant parasites as well as several macrocyclic lac-
tone–resistant parasites [27].
We evaluated the efficacy of moxidectin against coinfections 
with hookworm and O. viverrini. A low efficacy was observed 
against O. viverrini for both drugs (CRs of 18% for moxidectin 
and 6.5% for ivermectin). Moderate CRs of 57% and 56% against 
hookworm infection were recorded for moxidectin and iver-
mectin, respectively. Of note, we did not distinguish the activ-
ity against different hookworm species, including Ancylostoma 
ceylanicum, which is common in the study area [31] and should 
be evaluated in follow-up studies. Studies on the efficacy of iver-
mectin against hookworm infections in humans are scarce. Three 
studies revealed low CRs of 11.8%–33.1% for ivermectin against 
hookworm infections [32–34]. In veterinary medicine, on the 
other hand, both drugs are successfully used for the treatment 
of Ancylostoma spp. and other gastrointestinal parasites [35, 
36]. In dogs, for example, ivermectin was administered against 
Ancylostoma caninum infections, yielding CRs of 100% [35]. 
Similarly, moxidectin as pour-on or oral formulation demon-
strated a high efficacy against gastrointestinal nematodes in beef 
cattle [36]. The most widely used strategy for protecting against 
drug resistance is to use drug combinations [37]. Hence, it might 
be worth exploring the use of moxidectin in combination with 
albendazole. Considering the moderate effect of moxidectin 
against hookworm and the moderate efficacy of albendazole 
against S. stercoralis together with the similar distribution of these 
parasites, the combination might be effective in tackling the men-
tioned infections, while potentially delaying drug resistance.
We conclude that moxidectin might be a safe and efficacious 
alternative to ivermectin for the cure of S. stercoralis infection. 
We did not observe any ancillary benefit against coinfection with 
O. viverrini and moderate efficacy against hookworm. Larger tri-
als are needed to confirm our findings once the drug has success-
fully passed FDA registration and is marketed for human use.
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